Aaron Jamison

Aaron Jamison

Auto-generated profile, based on publicly available information

Aaron Jamison

Corneoplastic Unit, Queen Victoria Hospital NHS Foundation Trust, East Grinstead, UK

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 November 2020 in Ophthalmic Plastic & Reconstructive Surgery
Verified
Journal Article
Closed access
AJAaron Jamison
Aaron Jamison
CDCharles Diaper
Charles Diaper
SDSuzannah Drummond
Suzannah Drummond
DTDeepak Tejwani
Deepak Tejwani
MGMaria Elena Gregory
Maria Elena Gregory
VCVikas Chadha
Vikas Chadha
Purpose: Our oculoplastic service piloted a new video consultation (VC) clinic in response to the COVID-19 pandemic. Data were collected to determine whether specific patients are better suited to VC, and to quantify the true benefit of VC in patients that successfully attended. Methods: Data were collected prospectively on predetermined data collection forms, including consultation duration, diagnosis, management plan, and issues that arose. Results: 37.8% of new referrals and 60.9% of return patients were vetted as suitable for VC. Of those invited to attend, 83.4% agreed to a VC appointment. Of the patients appointed to a VC clinic, 71.7% (new)/75% (return) successfully completed VC, 14.9%/15.8% attempted a VC which ultimately failed, and 13.4%/9.2% did not attend. VC successfully prevented face-to-face consultation in 81.3% of new cases and 91.1% of returns. Ectropion, entropion and dermatochalasis (new referrals), and postoperative follow-up (return patients) were well suited to VC, while patients with “watery eye” (new), and lid or conjunctival lesions (return), often required face-to-face consultation. Problems (most common issues with patients connecting to the consultation, video quality, and audio quality) were encountered during 50.3% of calls, although 82.6% of attempted calls were ultimately successful. Age was not associated with the proportion of calls that were successful. Conclusions: VC is a useful tool for oculoplastic patients, irrespective of age, as long as the patient’s notes/referrals are carefully vetted to determine suitability. Patients with ectropion, entropion and dermatochalasis, and postoperative reviews are better suited to VC than those with “watery eye,” lid lesions, and conjunctival lesions.

25 October 2019 in Eye
Verified
Journal Article
Closed access
PDF file
AJAaron Jamison
Aaron Jamison
LBLesley A. Bhatti
Lesley A. Bhatti
MSManvi M. Sobti
Manvi M. Sobti
VCVikas Chadha
Vikas Chadha
PCPaul Cauchi
Paul Cauchi
EKEwan G. Kemp
Ewan G. Kemp

14 June 2022 in Aesthetic Surgery Journal
Verified
Journal Article
Closed access
PDF file
AJAaron Jamison
Aaron Jamison
LOLinda Okafor
Linda Okafor
KUKatja Ullrich
Katja Ullrich
VSVivian Schiedler
Vivian Schiedler
RMRaman Malhotra
Raman Malhotra
Prostaglandin analogues (PGAs; a first-line anti-glaucoma treatment) have been re-marketed as popular eyelash lengthening serums due to their lash lengthening and thickening side-effects. Periorbital volume loss is now a well-established side-effect of topical PGAs used to treated glaucoma (prostaglandin-associated periorbitopathy [PAP]) but has not, to date, been listed as a potential side-effect of lash lengthening serums containing PGA. To identify whether periorbital fat/volume loss is seen in users of prostaglandin analogue lash lengtheners. A case report and informal randomised controlled study comparing “before-and-after” colour photos displayed on the websites of PGA-containing lash lengtheners (PGALL) (i.e., containing bimatoprost, norbimatoprost, isopropyl cloprostenate, dechloro-dihydroxy-difluoro-ethylcloprostenolamide, or methylamido-dihydro-noralfaprostal), compared with two control groups: non-PGALL (NPGALL); false eyelashes (FL). Expert and layperson blinded graders used a purpose-designed grading system to identify subtle signs of periorbital fat/volume loss over time. A 35-year-old female developed thin, wrinkled, darker skin and periorbital hollowing within 10-months of using Lash Boost (Rodan & Fields, San Francisco, CA), containing isopropyl cloprostenate, which reversed six months after discontinuation. Fifteen “before-and-after” image pairs (PGALL, n=10; NPGALL, n=3; FL, n=2) were graded by five graders (three expert, two layperson). Mean grading score was 8.2 (of 19) in the PGALL group: NPGALL, 2.3; FL, 3.2. PGALL scores were significantly higher than NPGALL (p<0.001) and FL (p=0.017) groups. Review of commercial “before-and-after” photos suggests PGALL users develop changes compatible with PAP. Consumers must be aware of the possibility of periorbital volume loss prior to commencing PGALLs. Often the customer-facing product ingredient list contains no mention of PGA

6 June 2018 in Eye
Verified
Journal Article
Closed access
PDF file
AJAaron Jamison
Aaron Jamison
LBLarry Benjamin
Larry Benjamin
DLDavid Lockington
David Lockington

29 July 2013 in Orbit
Verified
Journal Article
Closed access
PDF file
AJAaron Jamison
Aaron Jamison
MGMaria Elena Gregory
Maria Elena Gregory
DLDouglas A. M. Lyall
Douglas A. M. Lyall
EKEwan G. Kemp
Ewan G. Kemp
Background: The risks of orbital biopsy depend on the lesion’s location and relationship with surrounding structures. Complications include reduced vision, although visual outcomes following orbital biopsy are not widely reported. Aims: To determine visual outcomes following orbital biopsy in Gartnavel General Hospital’s Oculoplastic and Oncology Service. Methods: Case note review of 50 consecutive patients undergoing orbital incision or excision biopsy between January 2006 and December 2010. Data collected included preoperative clinical examination, radiological and histological features, preoperative and postoperative corrected distance visual acuity (CDVA) and surgical complications. The main outcome measure was change in CDVA. Mean follow-up duration was 1.32 years. Results: Histological diagnoses following biopsy included idiopathic orbital inflammation (n = 13) and lymphoma (n = 9). Of the radiologically defined lesions, 86.7% were extraconal (13.3% intraconal). Extraconal lesions were anterior in 59.0% (41.0% posterior). Mean preoperative LogMAR CDVA was 0.10 which was maintained at day one post-biopsy, indicating the absence of immediate sight-threatening complications such as retrobulbar haemorrhage or optic nerve compression, and there was no significant reduction at one-year follow-up (p = 0.239). Further analysis of change in CDVA showed no difference between: anterior and posterior lesions; extraconal and intraconal lesions; incision and excision biopsies; anterior and lateral surgical approaches. Conclusions: CDVA is retained for one year following orbital biopsy. Significant visual loss is a very rare complication of this procedure.

29 May 2015 in Eye
Verified
Journal Article
Closed access
AJA Jamison
A Jamison
DGD F Gilmour
D F Gilmour